Dr. Glenn Reynolds is a practicing interventional cardiologist and is responsible for medical affairs Rubicon’s drug candidates. Dr. Reynolds is Board Certified and has practiced general and interventional cardiology at rural and urban practices and hospitals, large and small, including Boswell Hospital, a participant in the GUSTO cardiology thrombolytic trials and home of the Sun Health Research Institute, and the Arizona Heart Institute and Heart Hospital. He earned his MD degree at the Boston University School of Medicine.
He published a surgical technique to record and display venograms to guide placement of pacemaker leads, known as roadmapping. He was a research coordinator and principal investigator for the EPIC trial of abciximab (Reopro), a biologic drug still in use for acute coronary syndromes (Centocor, Lilly).